[go: up one dir, main page]

AR020876A1 - Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto - Google Patents

Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto

Info

Publication number
AR020876A1
AR020876A1 ARP990102696A ARP990102696A AR020876A1 AR 020876 A1 AR020876 A1 AR 020876A1 AR P990102696 A ARP990102696 A AR P990102696A AR P990102696 A ARP990102696 A AR P990102696A AR 020876 A1 AR020876 A1 AR 020876A1
Authority
AR
Argentina
Prior art keywords
compounds
binding
calcium channel
manufacture
pharmaceutical composition
Prior art date
Application number
ARP990102696A
Other languages
English (en)
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of AR020876A1 publication Critical patent/AR020876A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un compuesto multideslizante del canal de calcio caracterizado porque comprende de 2 a 10 ligantes los cuales pueden ser los mismos o diferentes y loscuales están covalentemente unidos a un enlazador o enlazadores, los cuales pueden ser los mismos odiferentes, cada uno de dichos ligantes abarcando undominio ligante capaz de enlazar a un canal Ca++. Los compuestos comprenden 2-10 ligantes conectados en forma covalente y cada uno de los ligantes es capaz deenlazarse a un sitio enlazante de ligante en un canal Ca++, modulando de esta manera las actividades biologicas del mismo. Además se describen compuestosmultienlazantes del canal de calcio, una composicion farmacéutica, uso de dichos compuestos para la manufactura de un medicamento, un método para identificarcompuestos multiméricos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multiméricos, y un método iterativo paraidentificar compuestos ligantes multiméricos.
ARP990102696A 1998-06-08 1999-06-08 Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto AR020876A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US9306898P 1998-07-16 1998-07-16
US10386698P 1998-10-12 1998-10-12

Publications (1)

Publication Number Publication Date
AR020876A1 true AR020876A1 (es) 2002-06-05

Family

ID=27375969

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102696A AR020876A1 (es) 1998-06-08 1999-06-08 Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto

Country Status (7)

Country Link
EP (1) EP1085863A1 (es)
JP (1) JP2002517440A (es)
AR (1) AR020876A1 (es)
AU (1) AU4549399A (es)
CA (1) CA2318901A1 (es)
SG (1) SG80038A1 (es)
WO (1) WO1999063992A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101909B2 (en) 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
CA2525970C (en) 2003-05-15 2011-03-22 Roskamp Research, Llc Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
JP5411145B2 (ja) 2007-10-05 2014-02-12 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド （−）−ニルバジピンエナンチオマーによってアミロイド沈着、アミロイド神経毒性、およびミクログリオーシスを減少させる方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042769A1 (de) * 1980-11-13 1982-06-09 Bayer Ag, 5090 Leverkusen C-3 verknuepfte 1,4-dihydropyridine, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
EP0510132B1 (en) * 1990-09-28 1997-05-14 Neorx Corporation Polymeric carriers for release of covalently linked agents
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
NZ280378A (en) * 1995-11-01 1998-04-27 Apotex Inc 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid compounds, preparation, intermediate compounds
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6403305B1 (en) * 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor

Also Published As

Publication number Publication date
WO1999063992A9 (en) 2002-08-22
WO1999063992A1 (en) 1999-12-16
EP1085863A4 (en) 2001-03-28
JP2002517440A (ja) 2002-06-18
EP1085863A1 (en) 2001-03-28
CA2318901A1 (en) 1999-12-16
WO1999063992A8 (en) 2001-02-22
SG80038A1 (en) 2001-04-17
AU4549399A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
AR020021A1 (es) Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal
ATE322266T1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
CY1114420T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη για την αγωγη της ψωριασης
ATE252919T1 (de) Zusammensetzungen und ihre verwendung zur verhütung von verklebungen zwischen körpergewebe
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
ATE256131T1 (de) Calanolide zur hemmung von btk
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
FI973039A0 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
ES2149044T3 (es) Metanosulfonato de paroxetina.
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
ES2192704T3 (es) Innovadoras composiciones farmaceuticas.
AR020876A1 (es) Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto
PT1263426E (pt) Preparacoes para a remocao nao traumatica de uma unha
PT1150681E (pt) Utilizacao de uma composicao farmaceutica que contem desoxipeganina para o tratamento da dependencia da nicotina
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
NO991867D0 (no) Biaromatiske forbindelser bundet via et heteroetynylenradikal, og farmas°ytiske og kosmetiske sammensetninger inneholdende dem
PT920336E (pt) Pesticidas que compreendem alcaloides da benzofenantridina
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
SV1997000010A (es) Nuevas heteroariloxazolidinonas ref. lea 31535-sv